

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A composition for treating solid tumor in a subject comprising a gene carrier or a cell harboring the gene carrier for expression in ~~human or~~ animal cells, ~~or ex vivo cells, harboring wherein the gene carrier comprises~~ a nucleic acid molecule encoding a recombinant protein consisting of human apolipoprotein(a) kringle KIV9-KIV10-KV (LK68) or KV (LK8) as an effective ingredient.

2. (Currently amended) The composition according to claim 1, wherein the LK68 encoding molecule comprises a nucleotide sequence represented by ~~SEQ ID No. 1~~ SEQ ID NO:1.

3. (Currently amended) The composition according to claim 1, wherein the gene carrier ~~harboring the LK68 encoding molecule~~ is a viral gene carrier vector or a non-viral gene carrier recombinant virus.

4. (Currently amended) The composition according to claim 3, wherein the non-viral gene carrier vector is selected from [[a]] linear DNA₂ vector, a plasmid DNA vector₁, liposome and [[a]] polyethyleneamine recombinant viral vector.

5. (Currently amended) The composition according to claim 3, wherein the viral gene carrier recombinant virus is selected from retrovirus, adenovirus, adeno-associated virus, herpes simplex virus and lentivirus.

6. (Currently amended) The composition according to claim 1, wherein the animal cells are selected from hematopoietic stem cells, dendritic cells, autologous tumor cells and established tumor cells.

7. (Currently amended) The composition according to claim 1, wherein the gene carrier is selected from pSecTag-LK68, pLXSN-LK68, rAAV-LK68₂ and pAAV-LK68₂, pSecTag-LK8, pLXSN-LK8, rAAV-LK8 and pAAV-LK8.

8. (Currently amended) The composition according to claim 1, wherein the LK8 encoding molecule comprises a nucleotide sequence represented by ~~SEQ-ID-No.2~~ SEQ ID NO:2.

9-12. (Canceled)

13. (Currently amended) The composition according to claim 3, wherein the non-viral gene carrier vector is ~~included by~~ present in an amount of 0.05 ~ 500 mg.

14. (Currently amended) The composition according to claim 3, wherein the viral gene carrier recombinant virus is ~~included by~~ present in an amount of $10^3 - 10^{12}$ IU.

15. (Currently amended) The composition according to claim 1, wherein the cells are ~~included by~~ present in an amount of $10^3 - 10^8$ e.a.

16. (Previously presented) The composition according to claim 1, wherein the solid tumor is selected from colon carcinoma, liver cancer, lung cancer, breast cancer, brain tumor, prostatic carcinoma, skin cancer, stomach cancer, pancreas cancer, lymphoma, kidney cancer, ovarian cancer and metastatic tumor.

17. (Previously presented) The composition according to claim 16, wherein the solid tumor is selected from colon carcinoma, liver cancer, lymphoma and metastatic tumor.

18. (Currently amended) A method for preventing or treating [[a]] solid tumor in a subject, which method comprises parenteral administration of comprising administering

parenterally to the subject a gene carrier, or *ex vivo* cells, harboring a nucleic acid molecule encoding a recombinant human apolipoprotein(a) kringle KIV9-KIV10-KV (LK68) or KV (LK8) ~~to an individual~~, wherein said gene carrier or *ex vivo* cells express said molecule to prevent or treat said solid tumor in the subject.

19. (Currently amended) The method according to claim 18, wherein the prevention or the treatment of a solid tumor in the subject is accomplished by inhibition of growth and metastasis of the solid tumor.

20. (Previously presented) The method according to claim 18, wherein the administration of a gene carrier harboring human apolipoprotein(a) kringle KIV9-KIV10-KV (LK68) or KV (LK8) encoding molecule is accomplished by a method selected from chemical method, physical method, conjugation using liposome, a method using receptor and virus.

21. (Currently amended) The method according to claim 18, wherein the administration is characterized by injecting cells selected from hematopoietic stem cells, dendritic cells, autologous tumor cells and established tumor cells transfected with human apolipoprotein(a) kringle KIV9-KIV10-KV(LK68) or KV(LK8) encoding molecule to a ~~patient~~ the subject.

22-23. (Canceled)

24. (New) The composition according to claim 5, wherein the viral gene carrier is adenovirus.

25. (New) The composition according to claim 5, wherein the viral gene carrier is adeno-associated virus.